| Aug 30 |
Biodexa gets delisting letter from Nasdaq
|
| Aug 30 |
Receipt of Nasdaq Delisting Determination - Plans to Appeal
|
| Aug 12 |
Biodexa Pharmaceuticals files for 4.35B ordinary shares for holders
|
| Jul 23 |
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
|
| Jul 19 |
Biodexa Pharmaceuticals announces pricing of $5M registered direct offering
|
| Jul 19 |
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
|
| Jul 16 |
How Is The Market Feeling About Biodexa Pharmaceuticals?
|
| Jul 16 |
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada
|
| Jul 11 |
Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why
|
| Jul 11 |
Biodexa stock rallies amid release of Phase 2 data for eRapa
|
